Skip to main content
TipRanks
Go Ultimate75% OFF

CytomX Therapeutics (CTMX) AI Stock Analysis

1,006 Followers
CTMX

CytomX Therapeutics

(NASDAQ:CTMX)

Select Model
Rating:45Neutral
Price Target:$2.00â–¼(-1.96% Downside)
Action:reiterated
Date:11/06/26

The score is held down primarily by weak financial performance (declining TTM revenue, sizable losses, and materially negative free cash flow indicating continued cash burn) and bearish technicals (price below key moving averages with negative MACD and weak momentum). These are partially offset by a constructive earnings call centered on advancing Varseta-M toward a potential registrational study, improving diarrhea management in optimization cohorts, and a projected cash runway into the second half of 2028.

Positive Factors
Differentiated Oncology PipelineVarseta-M’s potentially differentiated EpCAM-targeting design and Probody platform provide a focused basis for clinical and commercial positioning. Advancement toward a possible registrational study could create a durable value driver if the program confirms its early efficacy and safety advantages.
Negative Factors
Collaboration Revenue DeclineThe Astellas collaboration conclusion materially reduced reported revenue, highlighting CytomX’s dependence on collaboration and licensing economics while it remains clinical-stage. Lower partnership income can weaken internal funding capacity and increase reliance on milestone timing or future financing.

CytomX Therapeutics (CTMX) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%CTMX-44.26%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$444.73M
Dividend Yield
―
Average Volume (3M)
4.20M
Price to Earnings (P/E)
-4.5
Beta (1Y)
2.98
Revenue Growth
-87.66%
EPS Growth
-210.45%
Country
US
Employees
69
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CytomX Therapeutics Business Overview & Revenue Model

Company Description

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncologi...

How the Company Makes Money

CytomX primarily makes money through (1) collaboration and licensing arrangements and (2) to the extent achieved, development-related payments tied to partnered programs. Under these partnerships, CytomX can earn upfront payments (when agreements are...

CytomX Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-4.67%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with management highlighting progress toward a potential first registrational study for Varseta-M in the first half of 2027, encouraging progression-free survival, improved Grade 3 diarrhea results in dose optimization, expanding combination and pan-tumor programs, continued CX-801 enrollment, and cash runway into the second half of 2028. These positives were tempered by lower revenue following the Astellas collaboration conclusion, higher operating expenses, ongoing gastrointestinal toxicity management, and the delay of the monotherapy update to January.

Positive Updates

Varseta-M Advancing Toward First Registrational Study
CytomX is advancing Varseta-M toward its first potential registrational study in the first half of 2027. The company is initially developing the EpCAM-targeting topo-1 ADC in metastatic colorectal cancer, with the potential for a first approval and a meaningful market opportunity.

Negative Updates

Revenue Declined Following Astellas Collaboration Conclusion
Third-quarter 2026 total revenue was $1.7 million, down from $6.0 million in the third quarter of 2025. Management attributed the decrease primarily to the conclusion of the Astellas collaboration in the second quarter of 2026.

Company Guidance

CytomX expects to move Varseta-M monotherapy into a potential registrational study in the first half of 27, with an integrated update in January including the first look at overall survival, which is anticipated to be the primary endpoint in the initial registrational study; the bevacizumab combination is expected to report initial clinical data in the first half of 27, while the Varseta-M combination with bevacizumab, 5-fluorouracil and leucovorin is expected to start by the end of the year as a new Phase 1/2 trial, initially enrolling most likely late stage patients before the phase 2 part enrolls second line patients once phase 1 dose finding is successfully completed. CytomX has initiated gastrointestinal cohorts in unselected gastric and gastroesophageal junction cancer, EpCAM selected pancreatic ductal adenocarcinoma and EpCAM selected biliary tract cancer, with an initial plan to enroll approximately 20 patients per tumor type, and expects to report initial CX-801 melanoma data in the first half of 27. The company’s goal is to manage grade 3 diarrhea to 20% or below, and it projects cash runway into the second half of 28.

CytomX Therapeutics Financial Statement Overview

Summary

Overall fundamentals are weak: TTM revenue is down meaningfully (~-23%) and profitability has swung back to a large net loss after a profitable 2024, indicating high volatility. Cash generation is a major concern with materially negative TTM operating cash flow and free cash flow (about -$50M each), implying ongoing cash burn. The balance sheet helps somewhat with low reported leverage (debt-to-equity ~0.02), but inconsistent/occasionally negative equity and negative returns in TTM remain key risks.

Income Statement

28Negative

Balance Sheet

54Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue14.03M76.20M138.10M101.21M53.16M37.31M
Gross Profit13.78M76.20M138.10M101.21M53.16M37.31M
EBITDA-87.53M-15.75M33.86M5.50M-96.87M-113.16M
Net Income-85.42M-17.37M31.87M-569.00K-99.32M-115.87M
Balance Sheet
Total Assets364.68M151.57M120.53M201.79M260.89M339.41M
Cash, Cash Equivalents and Short-Term Investments347.98M137.05M100.62M174.51M193.65M305.23M
Total Debt4.39M4.24M9.38M13.97M18.06M21.67M
Total Liabilities79.79M52.56M120.99M249.24M346.64M339.87M
Stockholders Equity284.89M99.01M-456.00K-47.45M-85.75M-459.00K
Cash Flow
Free Cash Flow-51.00M-75.81M-86.54M-56.88M-112.53M-120.64M
Operating Cash Flow-50.21M-75.59M-86.23M-56.03M-110.79M-119.03M
Investing Cash Flow-201.25M-59.74M99.70M-150.67M98.26M22.49M
Financing Cash Flow251.74M110.45M7.52M30.23M648.00K110.21M

CytomX Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price2.04

Price Trends

50DMA2.56Negative
100DMA3.02Negative
200DMA3.71Negative

Market Momentum

MACD-0.15Positive
RSI39.35Neutral
STOCH35.31Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTMX, the sentiment is Negative. The current price of 2.04 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.56, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 39.35 is Neutral, neither overbought nor oversold. The STOCH value of 35.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTMX.

CytomX Therapeutics Risk Analysis

CytomX Therapeutics disclosed 74 risk factors in its most recent earnings report. CytomX Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.Q2, 2026
2.Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.Q1, 2026
3.Our business may be affected by the evolving regulatory framework for AI TechnologiesQ4, 2025

CytomX Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CTMX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ARCTARCT54Neutral$240.96M-2.70-46.79%―-74.84%-25.04%
VSTMVSTM54Neutral$1.03B-4.42-359.49%―649.65%54.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BCYCBCYC50Neutral$235.88M-1.66-26.02%―194.79%43.93%
LXRXLXRX46Neutral$796.97M-12.32-38.44%―-45.62%21.16%
CTMXCTMX45Neutral$444.73M-4.52-33.97%―-87.66%-210.45%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%CTMXLXRXVSTMARCTBCYCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CTMX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CTMXCytomX Therapeutics Inc.2.04-1.51-42.54%
LXRXLexicon Pharmaceuticals1.790.3322.60%
VSTMVerastem Inc8.18-0.97-10.60%
ARCTArcturus Therapeutics8.361.6023.67%
BCYCBicycle Therapeutics3.37-3.09-47.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026